Skip to main content

Table 5 Continuous sedative and analgesic infusions

From: Effect of an analgo-sedation protocol for neurointensive patients: a two-phase interventional non-randomized pilot study

  Observational period
(n = 106, days = 553)
Intervention period
(n = 109, days = 556)
P Value
Propofol days (% of total days) 307 (56%) 283 (51%) .006*
Mean dose/day (mg) ± SD 2,592 ± 1,623 2,074 ± 1,308 < .001*
Range (mg) 550 to 7,910 510 to 7,070  
Midazolam days (% of total days) 49 (9%) 80 (14%) .078
Mean dose/day (mg) ± SD 238 ± 152 157 ± 122 .001*
Range (mg) 3 to 485 0 to 425  
Fentanyl days (% of total days) 137 (25%) 114 (21%) .171
Mean dose/day (mcg) ± SD 2,303 ± 1,606 4,919 ± 3,588 < .001*
Range (mcg) 80 to 8,000 100 to 16,000  
Remifentanil days (% of total days) 297 (54%) 420 (76%) .281
Mean dose/day (mcg) ± SD 6,888 ± 5,373 8,233 ± 6,384 .003*
Range (mcg) 1,000 to 18,000 1,000 to 19,000  
Morphine days (% of total days) 41 (7%) 7 (1%) .009*
Mean dose/day (mg) ± SD 16 ± 9 10 ± 0 .077
Range (mg) 7 to 40 10 to 10  
Oxycodone days (% of total days) 67 (12%) 74 (13%) .199
Mean dose/day (mg) ± SD 25 ± 22 20 ± 14 .079
Range (mg) 5 to 100 3 to 69  
  1. Number of days (t-test), medication dose (Mann-Whitney), and * P value ≤ .05 significant. Range was calculated within limits of adequate sedation.